Trial watch: chemotherapy-induced immunogenic cell death in oncology

J Sprooten, RS Laureano, I Vanmeerbeek… - …, 2023 - Taylor & Francis
Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a …

RJ Motzer, BI Rini, DF McDermott, OA Frontera… - The Lancet …, 2019 - thelancet.com
Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab
showed superior efficacy over sunitinib in patients with previously untreated intermediate …

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma …

DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee… - European urology, 2014 - Elsevier
Background The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …

Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting

B Beuselinck, S Job, E Becht, A Karadimou… - Clinical cancer …, 2015 - AACR
Purpose: Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who
might benefit from treatment with targeted tyrosine kinase inhibitors (TKI) is a challenge. Our …

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

RS Laureano, J Sprooten, I Vanmeerbeerk… - …, 2022 - Taylor & Francis
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

MC Southey, DE Goldgar, R Winqvist… - Journal of medical …, 2016 - jmg.bmj.com
Background The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate
precisely associated cancer risks. Population-based family studies have provided evidence …

Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival

S Dudani, G De Velasco, JC Wells, CL Gan… - JAMA network …, 2021 - jamanetwork.com
Importance There exists considerable biological and clinical variability between histologic
variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns of metastasis …

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz… - The lancet …, 2019 - thelancet.com
Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on
the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with …

[HTML][HTML] Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib

B Beuselinck, S Oudard, O Rixe, P Wolter, A Blesius… - Annals of oncology, 2011 - Elsevier
Background The aim of our study was to determine whether the presence of bone
metastases affects outcomes in patients with metastatic clear-cell renal cell carcinoma (m …

Sunitinib for the treatment of metastatic renal cell carcinoma

S Oudard, B Beuselinck, J Decoene, P Albers - Cancer treatment reviews, 2011 - Elsevier
Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor approved
multinationally for the first-and second-line treatment of metastatic renal cell carcinoma …